Recently, China’s Sinovac announced that its inactivated hepatitis A vaccine has been awarded an exclusive two-year national procurement contract by Oman. This marks the first time Sinovac has secured a large-scale government tender in Oman, highlighting its expanding presence in the Middle Eastern market. Hepatitis A is an acute liver disease caused by the hepatitis A virus, primarily transmitted through contaminated food and water. Sinovac’s hepatitis A vaccine, developed using inactivated virus technology, is known for its strong safety profile and immunogenicity. It has been widely used in China and multiple international markets and has received WHO prequalification. The successful bid underscores the Omani government’s confidence in the quality and efficacy of Sinovac’s vaccine and reflects the growing role of Chinese biopharmaceutical products in global public health collaboration. This partnership may serve as a strategic gateway for Sinovac to further penetrate Gulf Cooperation Council (GCC) countries and other emerging markets, accelerating the internationalization of its vaccine portfolio.
近日，中国科兴生物（Sinovac）宣布其甲型肝炎灭活疫苗成功独家中标阿曼为期两年的国家采购订单。这是科兴疫苗首次在阿曼实现大规模政府采购，标志着其产品在中东市场的进一步拓展。甲型肝炎是一种由甲肝病毒引起的急性肝病，主要通过受污染的食物和水传播。科兴的甲肝疫苗采用灭活技术，具有良好的安全性和免疫原性，已在中国及多个国际市场广泛应用，并获得世界卫生组织（WHO）预认证。此次中标不仅体现了阿曼政府对科兴疫苗质量与有效性的高度认可，也反映出中国生物制品在国际公共卫生合作中的日益重要角色。未来，科兴有望借助此次合作，进一步打开海湾地区及其他新兴市场的大门，推动更多疫苗产品的国际化进程。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/19479.html